AI English summary of an SEC filing — figures as filed
Agilent Technologies AAgilent said in a press release dated December 20, 2023 that it moved its Cell Analysis Division from the Life Sciences and Applied Markets Group to the Diagnostics and Genomics Group. The three business segments, LSAG, DGG and Agilent CrossLab, will each remain a reportable segment.
Key points
AI summaryAgilent said in a press release dated December 20, 2023 that it moved its Cell Analysis Division from the Life Sciences and Applied Markets Group to the Diagnostics and Genomics Group. The three business segments, LSAG, DGG and Agilent CrossLab, will each remain a reportable segment.
The company said its financial statements will reflect the new reporting structure beginning with the quarter ending January 31, 2024, with prior periods recast accordingly. It said the filing furnishes selected segment information reflecting the changes in its reportable segments, as shown in the 8-K.
Agilent reported recast full-year FY23 revenue of $3,510 million for the Life Sciences and Applied Markets segment, with income from operations of $1,049 million (operating margin of 29.9%). On the same basis, full-year FY22 revenue was $3,630 million and income from operations was $1,097 million.
The company reported recast full-year FY23 revenue of $1,755 million for the Diagnostics and Genomics segment, with income from operations of $363 million (operating margin of 20.7%). On the same basis, full-year FY22 revenue was $1,766 million and income from operations was $390 million.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Move of Cell Analysis Division and three segments retained
Agilent said in a press release dated December 20, 2023 that it moved its Cell Analysis Division from the Life Sciences and Applied Markets Group to the Diagnostics and Genomics Group. The three business segments, LSAG, DGG and Agilent CrossLab, will each remain a reportable segment.
Source · Based on the filing body and exhibits
New structure effective from quarter ended January 31, 2024
The company said its financial statements will reflect the new reporting structure beginning with the quarter ending January 31, 2024, with prior periods recast accordingly. It said the filing furnishes selected segment information reflecting the changes in its reportable segments, as shown in the 8-K.
Source · Based on the filing body and exhibits
Additional information
Agilent reported recast full-year FY23 revenue of $3,510 million for the Life Sciences and Applied Markets segment, with income from operations of $1,049 million (operating margin of 29.9%). On the same basis, full-year FY22 revenue was $3,630 million and income from operations was $1,097 million.
Source · Based on the filing body and exhibits
Other disclosures
The company reported recast full-year FY23 revenue of $1,755 million for the Diagnostics and Genomics segment, with income from operations of $363 million (operating margin of 20.7%). On the same basis, full-year FY22 revenue was $1,766 million and income from operations was $390 million.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…